The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...

Enfortumab vedotin in combination with pembrolizumab is being investigated in an extensive program in multiple stages of urothelial cancer, including two Phase 3 clinical trials in MIBC in EV-304 ...

Enfortumab vedotin was given at 1.25 mg/kg on days 1 and 8 of every 3-week cycle, with no maximum number of cycles. Pembrolizumab was given at 200 mg on day 1 for up to 35 cycles.

Source Reference: Hoimes CJ, et al "Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer" J Clin Oncol 2022; DOI: 10.1200/JCO.22.01643.

Enfortumab vedotin has been approved for treatment-refractory advanced urothelial carcinoma since late 2019. However, we have limited data regarding biomarkers that can predict outcomes with ...

Enfortumab vedotin targets Nectin-4, a protein present in most urothelial cancer cells, delivering a cancer-killing agent directly into tumors. Pembrolizumab helps the immune system detect and ...

“Enfortumab vedotin is the first drug, beyond chemotherapy and immunotherapy, to show a significant survival advantage in previously treated advanced urothelial cancer,” Powles said.